A5089392636- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
- Animal Virus Infections Studies
- Viral gastroenteritis research and epidemiology
- Clostridium difficile and Clostridium perfringens research
- Chronic Lymphocytic Leukemia Research
- Gastrointestinal motility and disorders
- Immune Cell Function and Interaction
- Immunodeficiency and Autoimmune Disorders
- Colorectal Cancer Treatments and Studies
- Infection Control in Healthcare
- Helicobacter pylori-related gastroenterology studies
- COVID-19 diagnosis using AI
- Herbal Medicine Research Studies
- Systemic Lupus Erythematosus Research
- Radiomics and Machine Learning in Medical Imaging
- Microscopic Colitis
- AI in cancer detection
- Safe Handling of Antineoplastic Drugs
- Medical Device Sterilization and Disinfection
- Lung Cancer Treatments and Mutations
GlaxoSmithKline (India)
2024
Rzeszów University
2019-2024
College of Medical Sciences
2022
Pomeranian Medical University
2017
Bepirovirsen is an antisense oligonucleotide that targets all hepatitis B virus (HBV) messenger RNAs and acts to decrease levels of viral proteins.
Steatotic liver disease (SLD) can worsen the prognosis of other chronic diseases, including viral hepatitis. To compare SLD and non-SLD patients with hepatitis B virus (HBV) infection. The study included consecutive Caucasian treated nucleos(t)ide analogs (NA), entecavir or tenofovir, for a median (quartile 1-3) 6 (2-11) years evaluated between January 2023 June 2024. Of 273 in analysis, 86 were diagnosed SLD. Men dominated overall population, but their percentage was higher group (77.9% vs....
Background In the B-Clear study, bepirovirsen 300 mg for 24 weeks achieved hepatitis B surface antigen (HBsAg) and virus (HBV) DNA<lower limit of quantification (LLOQ) in 9% participants on nucleos[t]ide analogues (NA). The B-Together study assessed if sequential bepirovirsen/pegylated interferon (PegIFN) therapy can improve efficacy rates.
Was to assess current prevalence of hepatitis C virus (HCV) genotypes in Poland, including their geographic distribution and changes a given period time.Data were collected with questionnaires from 29 Polish centers included data patients diagnosed HCV infection between 1 January 2013 31 March 2016.In total, 9800 reported. The highest was estimated for genotype 1b (81.7%), followed by 3 (11.3%), 4 (3.5%), 1a (3.2%) 2 (0.2%). Genotype 5 or 6 reported only (0.1%). observed central (łódzkie,...
AMA Flisiak R, Pogorzelska J, Berak H, et al. Efficacy of HCV treatment in Poland at the turn interferon era – EpiTer study. Clinical and Experimental Hepatology. 2016;2(4):138-143. doi:10.5114/ceh.2016.63870. APA Flisiak, R., Pogorzelska, J., Berak, H., Horban, A., Orłowska, I., & Simon, K. (2016). Hepatology, 2(4), 138-143. https://doi.org/10.5114/ceh.2016.63870 Chicago Robert, Joanna Hanna Andrzej Iwona Krzysztof Ewelina Tuchendler 2016. "Efficacy study". Hepatology 2 (4): Harvard K.,...
In Europe, health-care policies are determined at a national level and differ between countries. This analysis from prospective, longitudinal, non-interventional study aimed to describe patterns in the clinical monitoring treatment of chronic hepatitis B (CHB) five European countries.Country-specific cohorts adult patients with compensated CHB managed clinics Germany, France, Poland, Romania Turkey were followed for up 2 years March 2008 December 2010.A total 1,267 included. Baseline age...
Abstract The outbreak of the SARS-CoV-2 pandemic has put healthcare systems worldwide to their limits, resulting in increased waiting time for diagnosis and required medical assistance. With chest radiographs (CXR) being one most common COVID-19 methods, many artificial intelligence tools image-based detection have been developed, often trained on a small number images from COVID-19-positive patients. Thus, need high-quality well-annotated CXR image databases increased. This paper introduces...
Chronic hepatitis B (CHB) is an important health concern, but there are few studies describing its management in different countries. This prospective, longitudinal, non-interventional study aimed to assess differences CHB five European countries (Germany, France, Poland, Romania and Turkey).Data were collected from patients' records between 2008 2010. Patients stratified by treatment status at baseline (treated or untreated). The primary objective was estimate the probability of a...
Abstract The MODIFY I/II trials demonstrated that bezlotoxumab, a human monoclonal antibody against Clostridioides difficile toxin B, given during antibiotic treatment for infection (CDI) significantly reduced C. recurrence (rCDI) in adults at high risk rCDI. Efficacy of CDI-directed intervention may depend on ribotype regional epidemiology, and patient characteristics. This post hoc analysis assessed the efficacy bezlotoxumab subgroup trial participants enrolled Europe. Data from (10 mg/kg...
Abstract In a multicentre, genome‐wide association study to identify host genetic factors associated with treatment response in adult chronic hepatitis B patients, genotype data were obtained by microarray analysis from 1669 patients who received peginterferon alfa‐2a for ≥ 24 weeks with/without nucleos(t)ide analog. Treatment was assessed at least post‐treatment, using serological and/or virological endpoints. Thirty‐six single‐marker analyses and gene‐by‐gene conducted. No single...
Introduction. Occupational exposure to potentially infectious material (PIM) is a serious problem for healthcare workers, including medical students. Aim. We assessed the state of knowledge about occupational and frequency among students selected faculties in Poland. Material methods. Retrospective analysis with proprietary questionnaires. Results. Only 34.5% from 753 respondents correctly indicated bloodborne pathogens 9.3% PIM. There were 84 reports exposure, mostly during intravenous...
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Pleśniak R, Wawrzynowicz-Syczewska M. Prevalence of hepatitis delta infections among HBs-antigen-positive inhabitants southeastern and northwestern parts Poland. Clinical Experimental Hepatology. 2019;5(3):232-236. doi:10.5114/ceh.2019.87636. APA Pleśniak, R., & Wawrzynowicz-Syczewska, (2019). Hepatology, 5(3), 232-236. https://doi.org/10.5114/ceh.2019.87636 Chicago Robert, Marta Wawrzynowicz-Syczewska. 2019....
Background: HBsAg is synthesized in the endoplasmic reticulum and necessary for formation of complete HBV particles. A decreased synthesis this antigen leads to an intracellular inhibition virus production. Methods: The study aimed assess incidence elimination among 1,290 patients who suffered from chronic infection undergoing antiviral treatment with nucleoside or nucleotide analogs (NAs). Furthermore, possible predictive factors were analyzed. Results: permanent loss was confirmed 3%...
To define the threats and epidemiological differences between outbreaks of hepatitis A (HA) in adults children, to assess efficiency implemented prophylaxis. We also present a summary treatment sick leave costs as compared predicted money-load case properly initiated prophylaxis virus (HAV)-exposed persons.The cause two was contamination related food mishandling by person infected with HAV. Especially health-threatening exposure infection 137 pre-school children. second outbreak caused same...
Background: The quantification of hepatitis B surface antigen (qHBsAg) was proposed as a helpful tool to monitor treatment efficacy with nucleos(t)ide analogs (NA) in HB e antigen-negative chronic HB. Objectives: present study aimed assess the effect entecavir (ETV) and tenofovir dipivoxil (TDF) on qHBsAg kinetics estimate time necessary achieve HBsAg clearance each these drugs. Methods: conducted 93 patients, 54 39 whom were treated ETV TDF for median 42 months, respectively. measured...
Celem leczenia przewlekłego wirusowego zapalenia wątroby typu B (pwzw B), zgodnym z ustaleniami najważniejszych towarzystw naukowych, jest poprawa jakości życia oraz przeżywalności pacjentów, którą można osiągnąć poprzez zahamowanie progresji choroby do marskości, niewydolności narządu czy rozw